📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. (2020)

First Author: Angwin C

Attributed to: MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-042784

PubMed Identifier: 33371044

Publication URI: http://europepmc.org/abstract/MED/33371044

Type: Journal Article/Review

Volume: 10

Parent Publication: BMJ open

Issue: 12

ISSN: 2044-6055